MX2023012647A - Acidos ribonucleicos modificados y sus usos. - Google Patents

Acidos ribonucleicos modificados y sus usos.

Info

Publication number
MX2023012647A
MX2023012647A MX2023012647A MX2023012647A MX2023012647A MX 2023012647 A MX2023012647 A MX 2023012647A MX 2023012647 A MX2023012647 A MX 2023012647A MX 2023012647 A MX2023012647 A MX 2023012647A MX 2023012647 A MX2023012647 A MX 2023012647A
Authority
MX
Mexico
Prior art keywords
ribonucleic acids
modified ribonucleic
same
modified
hydroxymethyluridine
Prior art date
Application number
MX2023012647A
Other languages
English (en)
Inventor
Kyle Backman
Nikhil Dhar
Nikolai Eroshenko
Marianna Keaveney
Justin Quinn
Everett Webster
Original Assignee
Helix Nanotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Nanotechnologies Inc filed Critical Helix Nanotechnologies Inc
Publication of MX2023012647A publication Critical patent/MX2023012647A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En la presente se describe un ribonucleótido modificado que comprende un nucleósido que comprende N4-acetilcitidina y/o 5-hidroximetiluridina, y polirribonucleótidos que los comprenden. En la presente también se proporcionan composiciones que comprenden un polirribonucleótido de la presente descripción, y métodos para la preparación y el uso de estas.
MX2023012647A 2021-05-07 2022-05-04 Acidos ribonucleicos modificados y sus usos. MX2023012647A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163185925P 2021-05-07 2021-05-07
US202163273031P 2021-10-28 2021-10-28
PCT/US2022/027721 WO2022235838A1 (en) 2021-05-07 2022-05-04 Modified ribonucleic acids and uses thereof

Publications (1)

Publication Number Publication Date
MX2023012647A true MX2023012647A (es) 2023-11-08

Family

ID=82058143

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012647A MX2023012647A (es) 2021-05-07 2022-05-04 Acidos ribonucleicos modificados y sus usos.

Country Status (9)

Country Link
US (4) US11639501B2 (es)
EP (1) EP4334330A1 (es)
JP (1) JP2024517681A (es)
KR (1) KR20240006603A (es)
AU (1) AU2022271246A1 (es)
CA (1) CA3214286A1 (es)
IL (1) IL308298A (es)
MX (1) MX2023012647A (es)
WO (1) WO2022235838A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022271246A1 (en) 2021-05-07 2023-11-30 Helix Nanotechnologies Inc Modified ribonucleic acids and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2937245T3 (es) 2005-08-23 2023-03-27 Univ Pennsylvania ARN que contiene nucleósidos modificados y métodos de uso del mismo
EP2931319B1 (en) * 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
LT6615B (lt) 2017-09-12 2019-04-25 Vilniaus Universitetas N4-modifikuoti citidino nukleotidai ir jų panaudojimas
WO2019213430A1 (en) * 2018-05-03 2019-11-07 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for nicking target dna sequences
WO2020077227A2 (en) 2018-10-12 2020-04-16 President And Fellows Of Harvard College Enzymatic rna synthesis
AU2022271246A1 (en) 2021-05-07 2023-11-30 Helix Nanotechnologies Inc Modified ribonucleic acids and uses thereof

Also Published As

Publication number Publication date
US20240026361A1 (en) 2024-01-25
JP2024517681A (ja) 2024-04-23
US20220372477A1 (en) 2022-11-24
IL308298A (en) 2024-01-01
US11639501B2 (en) 2023-05-02
WO2022235838A1 (en) 2022-11-10
EP4334330A1 (en) 2024-03-13
US20230407306A1 (en) 2023-12-21
AU2022271246A1 (en) 2023-11-30
KR20240006603A (ko) 2024-01-15
CA3214286A1 (en) 2022-11-10
US20230203488A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
WO2022155530A8 (en) Variant strain-based coronavirus vaccines
MX2021015894A (es) Peptidos acetales para estabilizar enzimas.
MX2020001903A (es) Novedoso polipeptido y procedimiento de produccion de imp mediante el uso del mismo.
WO2019126634A3 (en) Targeted integration of nucleic acids
BR112019006388A2 (pt) enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas
AU2019204119B2 (en) Novel polypeptide and method of producing IMP using the same
BR112015029601A2 (pt) produção de diterpeno extracelular
MX2021013581A (es) Composiciones de nanoemulsiones que comprenden ingredientes biologicamente activos.
EP4234587A3 (en) Thermally inhibited starch and process for making
MX2023012647A (es) Acidos ribonucleicos modificados y sus usos.
MX2021006745A (es) Constructos de iarn modificados quimicamente y usos de estos.
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
CO2022003608A2 (es) Cianopirrolidinas sustituidas con actividad como inhibidores de usp30
WO2020030984A3 (en) Compositions and methods for genome engineering with cas12a proteins
BR112021024080A2 (pt) Construtos de rnai para inibir a expressão de scap e métodos de uso dos mesmos
AU2018256256A1 (en) Method for producing dual function proteins and its derivatives
BR112022024501A2 (pt) Construtos de rnai para inibir a expressão de hsd17b13 e métodos de uso dos mesmos
MX2022002121A (es) Produccion de cannabinoides.
MX2022011077A (es) Variantes de transglutaminasa.
MX2021011480A (es) Produccion biosintetica de udp-ramnosa.
BR112021021601A2 (pt) Microrganismo geneticamente modificado e método de produção de ácido 3-hidroxiadípico, ácido a-hidromucônico e/ou ácido adípico
MX2021012813A (es) Conjugados de citocina de liberacion lenta.
MX2021006808A (es) Novedosa psicosa-6-fosfato fosfatasa, composicion para la produccion de psicosa que comprende la misma y procedimiento para la produccion de psicosa mediante el uso de la misma.
MX2022007907A (es) Composiciones enzimaticas y metodos para elaborarlas.
MX2022012561A (es) Composiciones y metodos para silenciar la expresion de la subunidad alfa tipo ix dependiente del voltaje del canal de sodio (scn9a).